

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Wong et al.

Application No. Not yet assigned

Filed: Herewith

Confirmation No. Not yet assigned

For: JAPANESE MACAQUE HERPESVIRUS
NUCLEIC ACID SEQUENCES AND
THEIR USE

Examiner: Not yet assigned

Art Unit: Not yet assigned

Attorney Reference No. 178-67426

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as Express Mail Label No. EV331581618US in an envelope addressed to: MAIL STOP PATENT APPLICATION, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent
for Applicant(s)

Date Mailed February 12, 2004

MAIL STOP PATENT APPLICATION
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
FOR CONTINUING APPLICATIONS

Listed on the accompanying form PTO-1449 are several English-language documents. Applicants respectfully request that such documents be listed as references cited on the issued patent.

The present application relies upon U.S. Patent Application No. 10/276,524, which was filed November 13, 2002, for an earlier filing date under 35 U.S.C. § 120. Furthermore, documents listed on the accompanying form PTO-1449 were disclosed to or cited by the Patent Office in the earlier U.S. application.

Copies of the documents listed on the accompanying form PTO-1449 that were cited by applicants in the earlier application need not be sent to the Patent Office pursuant to 37 C.F.R. § 1.98. However, applicants will furnish the Patent Office with such copies upon request.


Please charge any additional fees that may be required in connection with filing this Information Disclosure Statement, or credit any overpayment, to Deposit Account No. 02-4550. A duplicate copy of the transmittal sheet for this Information Disclosure Statement is enclosed.

The filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,


KLARQUIST SPARKMAN, LLP

By



Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446



INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	178-67426
	Application Number	Not yet assigned
	Filed	Herewith
	First Named Inventor	Wong
	Art Unit	Not yet assigned
	Examiner Name	Not yet assigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Name
		5,212,084	18 May 1993	McClure et al.
		5,214,066	25 May 1993	Szabo
		5,530,179	25 June 1996	Terhorst et al.
		5,543,131	06 Aug 1996	Levy
		5,569,812	29 Oct 1996	Monosov et al.
		5,625,128	29 Apr 1997	Wilson et al.
		5,667,766	16 Sep 1997	Wilson et al.
		5,698,766	16 Dec 1997	Julius et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Country
		WO 00/28040	18 May 2000	WIPO

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		Damania et al., <i>Journal of Virology</i> 73(6):5123-5131 (1999)
		Desrossiers et al., <i>Journal of Virology</i> 71(12):9764-9769 (1997)
		Kaleeba et al., <i>Journal of Virology</i> 73(7):6177-6181 (1999)
		Searles et al., <i>Journal of Virology</i> 73(4):3040-3053 (1999)

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	